Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Purchased by Victory Capital Management Inc.

Victory Capital Management Inc. increased its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 1.2% during the second quarter, Holdings Channel reports. The fund owned 137,543 shares of the company’s stock after acquiring an additional 1,676 shares during the quarter. Victory Capital Management Inc.’s holdings in Neurocrine Biosciences were worth $18,936,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of NBIX. International Assets Investment Management LLC boosted its position in Neurocrine Biosciences by 7,880.3% during the fourth quarter. International Assets Investment Management LLC now owns 5,666 shares of the company’s stock worth $747,000 after acquiring an additional 5,595 shares during the last quarter. Principal Securities Inc. acquired a new stake in Neurocrine Biosciences during the fourth quarter worth approximately $75,000. Dimensional Fund Advisors LP boosted its position in Neurocrine Biosciences by 1.8% during the fourth quarter. Dimensional Fund Advisors LP now owns 336,536 shares of the company’s stock worth $44,343,000 after acquiring an additional 5,907 shares during the last quarter. Envestnet Portfolio Solutions Inc. boosted its position in Neurocrine Biosciences by 3.2% during the fourth quarter. Envestnet Portfolio Solutions Inc. now owns 2,530 shares of the company’s stock worth $333,000 after acquiring an additional 78 shares during the last quarter. Finally, Principal Financial Group Inc. boosted its position in Neurocrine Biosciences by 10.7% during the fourth quarter. Principal Financial Group Inc. now owns 418,245 shares of the company’s stock worth $55,108,000 after acquiring an additional 40,289 shares during the last quarter. Institutional investors and hedge funds own 92.59% of the company’s stock.

Insider Buying and Selling at Neurocrine Biosciences

In other Neurocrine Biosciences news, insider Julie Cooke sold 12,632 shares of the business’s stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $153.26, for a total transaction of $1,935,980.32. Following the completion of the transaction, the insider now directly owns 18,202 shares of the company’s stock, valued at approximately $2,789,638.52. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other Neurocrine Biosciences news, Director William H. Rastetter sold 14,250 shares of the business’s stock in a transaction dated Thursday, August 15th. The shares were sold at an average price of $146.69, for a total transaction of $2,090,332.50. Following the completion of the transaction, the director now directly owns 37,491 shares of the company’s stock, valued at approximately $5,499,554.79. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Julie Cooke sold 12,632 shares of the business’s stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $153.26, for a total transaction of $1,935,980.32. Following the transaction, the insider now directly owns 18,202 shares of the company’s stock, valued at $2,789,638.52. The disclosure for this sale can be found here. Insiders sold 71,798 shares of company stock valued at $10,676,096 in the last ninety days. Company insiders own 4.30% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on NBIX. BMO Capital Markets decreased their price target on shares of Neurocrine Biosciences from $142.00 to $128.00 and set a “market perform” rating on the stock in a report on Thursday, August 29th. Robert W. Baird raised their target price on shares of Neurocrine Biosciences from $157.00 to $180.00 and gave the company an “outperform” rating in a research note on Friday, August 2nd. JPMorgan Chase & Co. lifted their price target on shares of Neurocrine Biosciences from $173.00 to $181.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 7th. Wedbush reaffirmed an “outperform” rating and set a $152.00 price target on shares of Neurocrine Biosciences in a research note on Wednesday, May 29th. Finally, StockNews.com raised shares of Neurocrine Biosciences from a “buy” rating to a “strong-buy” rating in a research report on Sunday, August 4th. Five research analysts have rated the stock with a hold rating, eighteen have given a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $162.20.

Neurocrine Biosciences Stock Performance

NASDAQ NBIX opened at $121.28 on Friday. Neurocrine Biosciences, Inc. has a one year low of $103.63 and a one year high of $157.98. The company has a 50-day simple moving average of $141.29 and a 200-day simple moving average of $138.66. The firm has a market capitalization of $12.21 billion, a PE ratio of 33.41 and a beta of 0.37.

Neurocrine Biosciences (NASDAQ:NBIX) last posted its earnings results on Thursday, August 1st. The company reported $0.63 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.15 by ($0.52). The firm had revenue of $590.20 million for the quarter, compared to analyst estimates of $545.98 million. Neurocrine Biosciences had a net margin of 16.00% and a return on equity of 14.86%. The company’s revenue for the quarter was up 30.4% on a year-over-year basis. During the same period in the previous year, the firm earned $0.95 earnings per share. Equities analysts forecast that Neurocrine Biosciences, Inc. will post 4.19 earnings per share for the current year.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.